Intensive blood pressure (BP) control targeting <130/80 mm Hg reduced cardiovascular events and mortality consistently across all baseline diastolic blood pressure (DBP) strata in a post hoc analysis of 33,288 participants from the China Rural Hypertension Control Project, with no evidence that lower DBP diminished benefit. Participants were categorized into […]
In patients with ST-segment elevation myocardial infarction (STEMI), early subcutaneous administration of zalunfiban significantly improved coronary artery patency and reduced the risk of adverse 30-day clinical outcomes without increasing severe bleeding. In an international, double-blind, placebo-controlled trial of 2,467 patients randomly assigned to receive zalunfiban (0.11 mg/kg or 0.13 mg/kg) […]
A systematic review and network meta-analysis evaluated the efficacy and safety of different exercise modalities for managing knee osteoarthritis, including aerobic, flexibility, mind-body, neuromotor, strengthening, and mixed exercises. A total of 217 randomized controlled trials involving 15,684 participants were analyzed, with outcomes assessed at short-term (4 weeks), mid-term (12 weeks), […]
An international, double-blind, placebo-controlled trial suggested that digitoxin modestly lowered the combined risk of death from any cause or hospital admission for worsening heart failure (HF) than placebo in patients with advanced HF receiving modern therapy. The trial evaluated digitoxin in 1,240 patients with chronic HF and reduced ejection fraction […]
A systematic review and meta-analysis of placebo-controlled randomized trials showed that there is moderate certainty evidence that non-steroidal anti-inflammatory drugs (NSAIDs) are efficacious for acute low back pain, and that exercise, spinal manipulative therapy, taping, antidepressants, and transient receptor potential vanilloid 1 (TRPV1) agonists are efficacious for chronic low back […]
Both clinician-rated and patient-reported outcomes suggested that mindfulness-based stress reduction (MBSR) was well-tolerated with comparable effectiveness to the first-line medication escitalopram for patients with anxiety disorders in a US randomized clinical trial. The trial included 276 participants (women 75%, men 25%; mean age 33 years; Asian 19%, Black 15%, Hispanic […]
In the prespecified analysis of a randomized, double-blind, placebo-controlled trial, bempedoic acid reduces LDL cholesterol, high-sensitivity C-reactive protein, and risk of cardiovascular events among those with baseline diabetes, prediabetes, or normoglycemia, with or without cardiovascular disease at baseline. Between Dec 22, 2016, and Nov 7, 2022, 13 970 patients who were […]
A prospective, randomized, double-blind, double-dummy, placebo and celecoxib (200 mg/day)-controlled trial concluded that a 800 mg/day pharmaceutical-grade Chondroitin sulfate (CS) is superior to placebo and similar to celecoxib in reducing pain and improving function over 6 months in symptomatic knee osteoarthritis (OA) patients. The trial included 604 patients of knee osteoarthritis in […]